Trial Profile
A randomized double-blind, placebo-controlled study of ABT-335 (fenofibric acid) to study the effect on meal-induced oxidative stress in patients with metabolic syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Choline fenofibrate (Primary)
- Indications Metabolic syndrome
- Focus Pharmacokinetics; Therapeutic Use
- 03 Dec 2015 New trial record